Department of Clinical Pharmacology and Therapeutics, Nizam's Institute of Medical Sciences, Hyderabad, India.
Clin Drug Investig. 2004;24(6):353-63. doi: 10.2165/00044011-200424060-00005.
Glucosamine, classified as a slow-acting drug in osteoarthritis (SADOA), is an efficacious chondroprotective agent. Methylsulfonylmethane (MSM), the isoxidised form of dimethyl-sulfoxide (DSMO), is an effective natural analgesic and anti-inflammatory agent. The aim of this study was to compare the efficacy and safety of oral glucosamine (Glu), methylsulfonylmethane (MSM), their combination and placebo in osteoarthritis of the knee.
A total of 118 patients of either sex with mild to moderate osteoarthritis were included in the study and randomised to receive either Glu 500mg, MSM 500mg, Glu and MSM or placebo capsules three times daily for 12 weeks. Patients were evaluated at 0 (before drug administration), 2, 4, 8 and 12 weeks post-treatment for efficacy and safety. The efficacy parameters studied were the pain index, the swelling index, visual analogue scale pain intensity, 15m walking time, the Lequesne index, and consumption of rescue medicine.
Glu, MSM and their combination significantly improved signs and symptoms of osteoarthritis compared with placebo. There was a statistically significant decrease in mean (+/- SD) pain index from 1.74 +/- 0.47 at baseline to 0.65 +/- 0.71 at week 12 with Glu (p < 0.001). MSM significantly decreased the mean pain index from 1.53 +/- 0.51 to 0.74 +/- 0.65, and combination treatment resulted in a more significant decrease in the mean pain index (1.7 +/- 0.47 to 0.36 +/- 0.33; p < 0.001). After 12 weeks, the mean swelling index significantly decreased with Glu and MSM, while the decrease in swelling index with combination therapy was greater (1.43 +/- 0.63 to 0.14 +/- 0.35; p < 0.05) after 12 weeks. The combination produced a statistically significant decrease in the Lequesne index. All treatments were well tolerated.
Glu, MSM and their combination produced an analgesic and anti-inflammatory effect in osteoarthritis. Combination therapy showed better efficacy in reducing pain and swelling and in improving the functional ability of joints than the individual agents. All the treatments were well tolerated. The onset of analgesic and anti-inflammatory activity was found to be more rapid with the combination than with Glu. It can be concluded that the combination of MSM with Glu provides better and more rapid improvement in patients with osteoarthritis.
氨基葡萄糖被归类为骨关节炎(OA)中的慢作用药物(SADOA),是一种有效的软骨保护剂。甲磺酰甲烷(MSM)是二甲亚砜(DMSO)的异氧化形式,是一种有效的天然止痛和抗炎剂。本研究旨在比较口服氨基葡萄糖(Glu)、甲磺酰甲烷(MSM)、两者联合应用和安慰剂治疗膝关节骨关节炎的疗效和安全性。
共纳入 118 例轻中度骨关节炎患者,分为 Glu 500mg、MSM 500mg、Glu 和 MSM 或安慰剂胶囊,每日 3 次,治疗 12 周。患者在治疗前(0 周)、治疗后 2、4、8 和 12 周进行疗效和安全性评估。研究的疗效参数包括疼痛指数、肿胀指数、视觉模拟评分疼痛强度、15m 步行时间、Lequesne 指数和止痛药物的消耗。
与安慰剂相比,Glu、MSM 及其联合应用显著改善了骨关节炎的体征和症状。Glu 组的平均(±SD)疼痛指数从基线时的 1.74±0.47 降至 12 周时的 0.65±0.71(p<0.001)。MSM 显著降低了疼痛指数,从 1.53±0.51 降至 0.74±0.65,联合治疗使疼痛指数的降低更为显著(1.7±0.47 降至 0.36±0.33;p<0.001)。治疗 12 周后,Glu 和 MSM 组的平均肿胀指数均显著下降,而联合治疗组的肿胀指数下降更大(1.43±0.63 降至 0.14±0.35;p<0.05)。联合治疗可显著降低 Lequesne 指数。所有治疗均耐受良好。
Glucosamine、Methylsulfonylmethane 及其联合应用在骨关节炎中具有镇痛和抗炎作用。与单独用药相比,联合治疗在减轻疼痛和肿胀以及改善关节功能能力方面显示出更好的疗效。所有治疗均耐受良好。联合治疗的镇痛和抗炎作用起效更快。可以得出结论,甲磺酰甲烷与氨基葡萄糖联合应用可更好、更快地改善骨关节炎患者的病情。